**Drug information**

**i. anti-infectives, ii. cytostatics, iii. others**

**BMJ**

K MacLure, D Stewart, A Strath. Robert Gordon University, School of Pharmacy & Life Sciences, Aberdeen, UK

**Background** The World Health Organization (WHO) defines eHealth as ‘the combined use of information and communications technologies for health’ [1]. eHealth strategies worldwide aim to promote quality, safety and efficiency by underpinning shared healthcare provision with technology. The Scottish eHealth Strategy incorporates an ePharmacy programme to support pharmacists’ increasing role in shared care [2]. It acknowledges organisational development and training for core and optional eHealth services as key.

**Purpose** To explore and report methodologies, findings and gaps in research related to healthcare professionals’ perceptions of the adoption of eHealth Technologies for shared care.

**Materials and Methods** A systematic review was conducted using a meta-narrative approach [3]. Articles published post-2004 in English were included; articles on Internet searches for health information or email were excluded. Data were extracted, synthesised and summarised. Ethical approval was not required.

**Results** Screening reduced the initial 327 papers identified to 12 which included three reviews, four qualitative, two mixed-methods and three quantitative studies. Data were collected using questionnaires (3), case study (1), group (2) and individual (6) interviews, observation (3) and extraction of data from records (1). Practice settings were remote rural or urban featuring primary care, secondary care or both. The focus was on electronic records (7), telemedicine (2) or general eHealth implementation (3) from the perspective of doctors, nurses, IT developers, policy makers and managers. One study included the views of a hospital pharmacist. Acceptance of eHealth technologies is reported but with cost effectiveness, resourcing and training questioned. Emerging themes are organisational, social and technical.

---

**DSL-022**

**Simplification of Antiretroviral Treatment with Darunavir/Ritonavir. The Financial Impact of Monotherapy**

doi:10.1136/ejhpharm-2013-000276.265


**Background** Currently, drugs for HIV treatment have an important financial impact in our hospital Pharmacy Department. Protease Inhibitor (PI) monotherapy is a useful tool that can be used for selected patients.

**Purpose** To determine the proportion of patients on antiretroviral therapy (ART) who could benefit from simplification to Darunavir/Ritonavir (DRV/r) and evaluate its financial impact.

**Materials and Methods** Retrospective study conducted in a primary hospital between September 2011 and September 2012. Patients included were those being treated for HIV infection. Simplification criteria [1] (CS) for DRV/r were the following: patients without a history of failure of Protease Inhibitors (PIs), undetectable viral load (VL < 50 c/mL) over the last 6 months, adherence to treatment >95% and/or intolerance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs). We excluded HIV-2 patients, those co-infected with chronic hepatitis B virus or already treated with PI monotherapy (DRV/r). Clinical data were collected from medical and dispensing records from outpatients.

**Results** Patients on ART: 346. Of those, 34 patients met the CS. Their previous ARTs were: 18 with 2 NRTI + 1 PI, 7 with 2 NRTI + 1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) and 9 with other ART. The most prevalent NRTIs, PIs and NNRTIs were tenofovir (76%), lopinavir (35%) and efavirenz (14%). There were 14 patients with no response to PIs, 68 with detectable VL, 89 with adherence <95% and 69 with intolerance to NRTIs. Average savings per patient/year: €3,246. Total savings: €110,378 per year (4.7% of the total HIV cost).

**Conclusions** Almost 10% of patients treated with HIV drugs could be on simplified treatment. 75% of previous ARTs were 2 NRTI plus 1 PI or NNRTI, which is consistent with reference clinical studies. Simplifying the treatment could improve adherence and tolerance in patients as well as cost effectiveness in the ambulatory management of these drugs.

**Reference**

1. EACS Clinical Guidelines, October 2011 (v.6).

No conflict of interest.

---

**DSL-023**

**The Cost Analysis of Introducing the Two-bin Replenishment System for Medical Devices, Antiseptics and Intravenous Fluids in a Geriatric Hospital**

doi:10.1136/ejhpharm-2013-000276.266

F Leleuy, P Golfin, G Simonet, V Chaumard, L Derain. Hospices Civils de Lyon, Pharmacie Centrale, Saint Genis Laval, France; Hospices Civils de Lyon, Pierre Garraud, Lyon, France

**Background** The two-bin replenishment system has been launched in some public hospitals of Lyon for medical devices, antiseptics and intravenous fluids.

**Purpose** To make a cost analysis of setting up the two-bin system in a hospital that has eleven wards.

**Materials and Methods** We identified the cost differences between the new two-bin replenishment system and the previous one from the perspective of the hospital.

**Self-assessment questionnaires** aimed to gather the following information:

- the time spent using the original system and the new one over a period of one week,
- the time spent setting up the new system.

The questionnaires were carried out on the wards, pharmacy and with the staff in charge of the setting up. Then we gave a value to the times collected using the amount charged for salaries in 2011.

The amount of products returned to the pharmacy was used as an indicator of the cost savings between the two systems. We also collected the cost of furniture.

We finally made an amortisation schedule of the collected costs.

**Results** Eight out of the eleven wards answered the self-assessment questionnaire. The value of staff time saved with the two bin replenishment system was found to be €13,800 per year. The difference in cost between the new and the original stock was around €7600. We compared these savings with the cost of setting up the new system. It cost €24,500 in manual labour expenses and €35,600 for the furniture and renovation works.

The amortisation schedule shows a return on investment in 3 years.

**Conclusions** This study reinforced our wish to develop this type of replenishment in our other public hospitals as its safety benefit has been published in a previous report (MEAH report – September 2006).

No conflict of interest.
Conclusions Strategies worldwide believe technology has the potential to promote quality, safety and efficiency in shared care where organisational, social and technical issues are addressed. However, evidence of hospital pharmacists’ views, their perceptions of eHealth and shared care, organisational development and training needs remain under-researched.

References

No conflict of interest.

DGI-002 ADRENAL INSUFFICIENCY INDUCED BY A CHINESE HERBAL MEDICINE
doi:10.1136/ejhpharm-2013-000276.268

M Kieran, C Gavin, L O’Shea, J Brady, C Meegan. Mater Misericordiae University Hospital, Pharmacy Department, Dublin, Ireland (Rep.); Mater Misericordiae University Hospital, Department of Endocrinology, Dublin, Ireland (Rep.); Mater Misericordiae University Hospital, Biochemistry Department, Dublin, Ireland (Rep.)

Background Chinese herbal medicines have a history, dating back to 1974, of containing strong prescription drugs [1]. In the United States (US), Food and Drug Authority (FDA) analysis of Chinese herbal preparations has found prednisolone, diazepam, paracetamol, indomethacin and hydrochlorothiazide [1].

During a routine review for type 2 diabetes, a MMUH patient reported new-onset fatigue. In view of the presenting complaint, a Synacthen test and thyroid function tests were performed. The patient’s Synacthen test reported positive for adrenal insufficiency, despite an absence of other clinical symptoms. Repeat testing and patient’s Synacthen test reported positive for adrenal insufficiency, indicating a potential diagnosis of drug-induced adrenal insufficiency.

Purpose To find out whether Cow’s Head Brand, Tung Shueh Pills contained corticosteroids.

Materials and Methods Literature review for reports on Cow’s Head Brand, Tung Shueh Pills. Analysis of Cow’s Head Brand, Tung Shueh Pills in collaboration with the Irish Medicines Board (IMB). Retail purchase of Tung Shueh Pills from Ang Pharmaceutical Company are included on a FDA list of containing strong prescription drugs [1].

No conflict of interest.